TRACON Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
TRACON Pharmaceuticals has been growing earnings at an average annual rate of 14.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 82.6% per year.
Anahtar bilgiler
14.5%
Kazanç büyüme oranı
59.0%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 82.6% |
| Özkaynak getirisi | n/a |
| Net Marj | 162.3% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Tracon Pharmaceuticals announces $35M non-dilutive debt facility
Sep 06Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma
Aug 29Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M
Aug 10TRACON Pharmaceuticals announces $5M registered direct offering
Dec 29TRACON Pharma launches $8.8M direct offering
Dec 22Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study
Dec 10Tracon Pharma files China application for envafolimab in solid tumors
Nov 16Gelir ve Gider Dağılımı
TRACON Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 3 | 5 | 5 | -5 |
| 31 Mar 24 | 12 | 2 | 6 | 0 |
| 31 Dec 23 | 12 | -4 | 7 | 0 |
| 30 Sep 23 | 9 | -11 | 7 | 8 |
| 30 Jun 23 | 9 | -28 | 8 | 8 |
| 31 Mar 23 | 0 | -28 | 10 | 0 |
| 31 Dec 22 | 0 | -29 | 14 | 0 |
| 30 Sep 22 | 0 | -30 | 17 | 0 |
| 30 Jun 22 | 0 | -30 | 19 | 0 |
| 31 Mar 22 | 0 | -33 | 21 | 0 |
| 31 Dec 21 | 0 | -29 | 18 | 0 |
| 30 Sep 21 | 0 | -25 | 15 | 0 |
| 30 Jun 21 | 0 | -22 | 13 | 0 |
| 31 Mar 21 | 0 | -18 | 9 | 0 |
| 31 Dec 20 | 0 | -17 | 8 | 0 |
| 30 Sep 20 | 0 | -16 | 8 | 0 |
| 30 Jun 20 | 0 | -18 | 8 | -3 |
| 31 Mar 20 | 0 | -19 | 8 | 0 |
| 31 Dec 19 | 0 | -23 | 8 | 0 |
| 30 Sep 19 | 0 | -26 | 8 | -5 |
| 30 Jun 19 | 0 | -30 | 8 | 0 |
| 31 Mar 19 | 0 | -34 | 7 | -2 |
| 31 Dec 18 | 3 | -35 | 7 | 0 |
| 30 Sep 18 | 3 | -34 | 7 | 7 |
| 30 Jun 18 | 10 | -24 | 7 | 6 |
| 31 Mar 18 | 11 | -20 | 7 | 6 |
| 31 Dec 17 | 9 | -19 | 8 | 0 |
| 30 Sep 17 | 9 | -19 | 8 | 7 |
| 30 Jun 17 | 3 | -26 | 8 | 7 |
| 31 Mar 17 | 3 | -28 | 8 | 7 |
| 31 Dec 16 | 3 | -27 | 8 | 6 |
| 30 Sep 16 | 4 | -32 | 8 | 6 |
| 30 Jun 16 | 5 | -32 | 7 | 6 |
| 31 Mar 16 | 8 | -27 | 7 | 6 |
| 31 Dec 15 | 8 | -24 | 6 | 5 |
| 30 Sep 15 | 8 | -16 | 5 | 4 |
| 30 Jun 15 | 8 | -12 | 4 | 4 |
| 31 Mar 15 | 4 | -10 | 3 | 3 |
| 31 Dec 14 | 4 | -7 | 2 | 3 |
| 30 Sep 14 | 3 | -7 | 2 | 2 |
| 30 Jun 14 | 1 | -7 | 2 | 2 |
| 31 Mar 14 | 0 | -8 | 2 | 2 |
Kaliteli Kazançlar: TCON has a large one-off gain of $15.0M impacting its last 12 months of financial results to 30th June, 2024.
Büyüyen Kar Marjı: TCON became profitable in the past.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: TCON has become profitable over the past 5 years, growing earnings by 14.5% per year.
Büyüme Hızlandırma: TCON has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Kazançlar vs. Sektör: TCON has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: TCON's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.